Please login to the form below

Opinion piece: Patient-centricity and pharma – where are we now?

Patient-centricity is a term that has gained currency in the pharma industry in recent years, and most major companies in the sector are now dedicating resources to ensure that they put the wishes and needs of patients centre-stage in all of their business activities.
But questions still remain before it is likely to be completely adopted by the pharma industry, such as how should the industry define what true patient-centricity is, and how should progress be measured?  

Following active monitoring of developments in patient-centricity this year, gauging sentiment in the industry about progress so far, and what work still needs to be done, in a recent webinar, Ashfield Healthcare Communications and pharmaphorum attempted to answer these big questions.  

The fundamentals to building a patient-centric business  

Earlier this year, Ashfield convened a patient forum of 12 representatives from pharma companies, including large, broad portfolio companies as well as smaller/mid-sized, more specialist providers. It invited contributions from a mix of people with patient-centred roles, from Chief Patient Officer through to regional and functional patient leads.  
The participants discussed their companies’ visions for patient-centricity, the strategy and structures they were putting in place, and the key challenges they were encountering. The forum was moderated by patient advocate and former cancer patient Andrew Schorr, co-founder and director of Patient Power, along with Ashfield.  
If you would like to understand more about the findings from the patient forum and our recent webinar, click here to read our article in full, or watch our webinar on demand here.  

This article was published by Ashfield Healthcare Communications, part of UDG Healthcare plc.

1st December 2016



Company Details


Contact Website

Ashfield House
Resolution Road
Ashby de la Zouch
LE65 1HW

Latest content on this profile

Ashfield wins Best Newcomer at the Pf Awards 2018
We are thrilled to announce that Zuchaela Smylie, from Ashfield, won Best Newcomer at the 2018 Pf Awards, the largest pharmaceutical sales awards in the UK. The awards ceremony took place on Thursday, 9 March at The Lancaster Hotel in London.
“It is evident that meeting face-to-face is still highly valued in the digital age”
Attending a scientific congress or meeting overtakes professional journals and publications as the educational channel of choice for Healthcare Professionals – according to findings of new study
Ashfield to present at the Orphan Drugs for Rare Diseases Summit
Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. We are delighted to be sponsoring and presenting at the ‘Orphan Drugs for Rare Diseases’ event 22-23 March in Berlin.
Addressing the biggest challenges for rare disease communities
Each year, Rare Disease Day takes place worldwide on the last day in February. The main objective of Rare Disease Day is to raise awareness amongst the general public, the healthcare industry and decision-makers about rare diseases and their impact on patients' lives.
Humanise is our strategic approach to healthcare communications. It’s based on the need to understand. It looks at the emotions that make us human. It examines the feelings we have as individuals. It defines the behaviours we show as people.
Ashfield launches new commercial model to improve ROI
Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution.